Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Introgen Awarded European Patent

  • Introgen Therapeutics was granted a broad patent by the European Patent Office that relates to the production of purified adenoviral compositions that are commercially scaleable and can be readily validated for regulatory purposes. This patent complements three previously issued U.S. patents related to the production of adenoviral vectors.

    "This patent is the European complement to our existing U.S. adenovirus production/purification technology,” David L. Parker, Ph.D., Introgen's senior vp of intellectual property. “It is of particular importance in that it covers the production of adenoviruses of commercial scale, quantity, and purity, regardless of whether the adenovirus is used as a delivery system for therapeutic genes, used directly as a therapeutic agent, used as a vaccine or vaccine component, or simply used for research and development purposes."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »